
Episode #9
The business behind biotech breakthroughs
Promising research is the starting point for bringing a scientific breakthrough to market. But a capital strategy that evolves alongside the company can be just as critical to success. On this episode of Navigating Beyond the Expected, Truist Securities’ Laura Chittick and Eugene Rozelman discuss how investor priorities shift over time and what that means for management teams preparing for pivotal decisions. They also explain why aligning the right form of capital for a stage of growth can help position biotech companies for long-term success. Also in the discussion: Why strong science alone isn’t enough to earn investor confidence How biotechs decide whether to commercialize, partner, or sell a technology The strategic tradeoffs between equity, debt, partnerships, and royalties How corporate and investment banking work together to support biotech companies New episodes of Navigating Beyond the Expected arrive each month, featuring conversations with top Truist Securities experts about the challenges businesses are facing now. Be sure to subscribe to hear every episode.

